IRLAB Therapeutics AB (publ)

OM:IRLAB A Stock Report

Market Cap: SEK 804.0m

IRLAB Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

IRLAB Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Buyback Yield

Total Shareholder Yieldn/a
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

Oct 30
Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

Jun 06
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

Jan 04
Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Sep 21
Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18
We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01
IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19
We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11
We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30
We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19
What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25
We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21
Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25
What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if IRLAB A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IRLAB A's dividend payments have been increasing.


Dividend Yield vs Market

IRLAB Therapeutics Dividend Yield vs Market
How does IRLAB A dividend yield compare to the market?
SegmentDividend Yield
Company (IRLAB A)n/a
Market Bottom 25% (SE)1.6%
Market Top 25% (SE)4.9%
Industry Average (Pharmaceuticals)2.7%
Analyst forecast (IRLAB A) (up to 3 years)n/a

Notable Dividend: Unable to evaluate IRLAB A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IRLAB A's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate IRLAB A's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IRLAB A has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 03:53
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IRLAB Therapeutics AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gonzalo Artiach CastanonABG Sundal Collier Sponsored
null nullABG Sundal Collier Sponsored
Soo RomanoffEdison Investment Research